¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acute hepatitis B without delta- agent and without hepatic coma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hepatic pulsation
    °£(Àå)¹Úµ¿.
  • hepatic pulse
    °£¸Æ(ÊÜØæ).
  • hepatic rickets
    °£¼º±¸·çº´(¡­ תܻ).
  • hepatic rickets
    °£¼º ±¸·çº´(¡­ תܻ).
  • hepatic sarcoid
    °£(ÊÜ)»ç¸£ÄÚÀ̵å.
  • hepatic siderosis
    °£Ã¶Áõ(ÊÜôÑñø).
  • hepatic status
    °£±â´É»óÇØ
  • hepatic status assessment
    °£±â´ÉÆò°¡
  • hepatic stupor
    °£¼ºÈ¥¹Ì(ÊÜàõûçÚ»).
  • hepatic sulfur
    °£È²(ÊÜüÜ).
  • hepatic triad
    °£¼¼µ¿ÀÌ
  • hepatic triglyceride lipase
    °£Áß¼ºÁö¹æ<Æ®¸®±Û¸®¼¼¶óÀ̵å>¸®ÆÄÁ¦
  • hepatic triglyceride lipase absence
    °£Áß¼ºÁö¹æ ¸®ÆÄÁ¦°á¿©(Áõ)
  • hepatic vein
    °£Á¤¸Æ.
  • hepatic vein thrombosis
    °£Á¤¸ÆÇ÷ÀüÁõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hepatic vein
    °£Á¤¸Æ.
  • hepatic vein thrombosis
    °£Á¤¸ÆÇ÷ÀüÁõ
  • hepatic veins
    °£Á¤¸Æ
  • hepatic venous wedge pressure =wedged h.vein pressure
    Æó»ö°£Á¤¸Æ¾Ð( øÍßáÊÜð¡Øæäâ).
  • hepatic yhypersensitivity
  • intermediate hepatic veins
    Áß°£°£Á¤¸Æ
  • jecoral =hepatic
    °£(ÊÜ)ÀÇ.
  • left hepatic artery<³ª> ramus sinister arteriae hepaticae propriae
    Á°£µ¿¸Æ
  • left hepatic branch artery<³ª> ramus sinister artery hepaticae propriae
    ¿Ü°úÁ°£Áö.
  • left hepatic duct
    ¿Þ°£°ü
  • left hepatic lobe
    ¿Þ°£¿±
  • left hepatic veins
    ¿Þ°£Á¤¸Æ
  • liver,hepatic encephalopathy
    °£¼º ³úº´Áõ(¡­ÒàÜ»ñø)
  • massive hepatic necrosis
    ±¤¹ü¼º °£±«»ç.
  • massive hepatic necrosis
    ±¤¹ü¼º °£±«»ç(ÎÆÛôàõ ÊÜÎÕÞÝ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
narco narcotic, narcotic addict, drug enforcement agent
NMB neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ...
NMBA neuromuscular blocking agent
NSAIA nonsteroidal anti-inflammatory agent
OCA oculocutaneous albinism; olivopontocerebellar atrophy; oral contraceptive agent
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
NHGO Net hepatic glucose output
NHGU Net hepatic glucose uptake
SHE Subclinical hepatic encephalopathy
THBF Total hepatic blood flow
TAE Transcatheter hepatic arterial embolization
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute infectious hemorrhagic fever
    ±Þ¼º °¨¿°¼º ÃâÇ÷ ¿­
  • acute infectious paralysis
    ±Þ¼º Àü¿°¼º ¸¶ºñ
  • acute inflammatory demyelinating polyradiculoneuropathy
    ±Þ¼º ¿°Áõ¼º ´Ù¹ß½Å°æ¿°
    ¾ÆÁ÷µµ È®½ÇÇÏÁö ¾ÊÁö¸¸ ¸é¿ª¹ÝÀÀÀ» ÅëÇÏ¿© ³ªÅ¸³­´Ù°í ¾Ë·ÁÁ® ÀÖ´Â ½Å°æº´ÁõÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ±Þ¼ÓÈ÷ ÁøÇàÇÏ´Â ¿îµ¿½Å°æº´ÁõÀ¸·Î ÇÏÁö¿¡¼­ ½ÃÀÛÇÏ¿© »óÁö·Î ÁøÇàµÇ¸ç, Á¤µµÀÇ Â÷À̸¦ °¡Áø °¨°¢Àå¾Ö¸¦ µ¿¹ÝÇÑ´Ù.
  • acute intermittent porphyria
    ±Þ¼º °£Ç漺 Æ÷ÇÁÇǸ°Áõ
    Æ÷¸£ÇǸ°Áõ °¡¿îµ¥ °¡Àå ¸¹Àº °ÍÀÌ°í ¾à°£ ¿©¼º¿¡°Ô ¸¹Àºµ¥ »ó¿°»öü ¿ì¼º À¯ÀüÀ» ÇÑ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. º¹Åë, ±¸Åä, º¯ºñ µîÀÇ º¹ºÎ Áõ»óÀÌ ±Þ¼º °£Ç漺À¸·Î »ý±â°í ¶§·Î´Â ¼±Åë°ú ºñ½ÁÇÒ ¶§°¡ ÀÖ´Ù. º¹ºÎ Áõ»ó¿¡ À̾î À̸¥¹Ù ´Ù¹ß¼º ½Å°æ¿°°ú °°Àº ½Å°æ Áõ»óÀÌ ³ªÅ¸³ª´Âµ¥, Á¤½Å Áõ»óµµ »ý±â´Â ¼ö°¡ ÀÖ´Ù. ¿ì·ÎÆ÷¸£ÇǸ®³ëÁ¨ 1ÀÇ ÇÕ¼º È¿¼ÒÀÇ À¯ÀüÀû ÀúÇϰ¡ ÀÖ°í Æä³ë¹ÙºñÅ» º¹¿ë µîÀÇ À¯Àο¡ ÀÇÇØ Çð ÇÕ¼ºÀÌ ´õ¿í ³·¾ÆÁö¸é Çǵå¹éÀûÀ¸·Î ¾Æ¹Ì³ë·¹ºê¸°»êÀ̳ª Æ÷¸£Æ÷ºô¸®³ëÁ¨ÀÇ Áõ»óÀÌ »ý±â°í ±× ¶§¹®¿¡ Áõ»óÀÌ ¹ß»ýÇÏ´Â °ÍÀ¸·Î µÇ¾î ÀÖ´Ù.
  • acute interstitial pneumonitis
    ±Þ¼º °£Áú¼º Æó·Å
  • acute isolated myocarditis
    ±Þ¼º ºÐ¸®¼º ½É±Ù¿°
  • acute lacunar tonsillitis
    ±Þ¼º ¼±¿Í Æíµµ¿°
  • acute laryngotracheal trauma
    ±Þ¼º Èĵαâ°ü ¿Ü»ó
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´
    ¿ø¹ßÇÏ´Â Á¶Ç÷ Á¶Á÷À̳ª ¹éÇ÷º´ ¼¼Æ÷ÀÇ Á¾·ù¿¡ µû¶ó °ñ¼ö¼º, ¸²ÇÁ¼º, ´Ü±¸¼ºÀ¸·Î ³ª´µ¾îÁö°í Ư¼öÇÑ °ÍÀ¸·Î¼­ Àû¹éÇ÷º´, ÇüÁú ¼¼Æ÷¼º ¹éÇ÷º´, È£»ê±¸¼º ¶Ç´Â È£¿°±â¼º ¹éÇ÷º´ µîÀÌ ÀÖ´Ù.
  • acute leukosis
    ±Þ¼º ¹éÇ÷Áõ
  • acute locking
    ±Þ¼º °úµÎ°É¸²
  • acute lymphangitis
    ±Þ¼º ¸²ÇÁ°ü¿°
    ¸²ÇÁ°ü³»¿¡ ¼¼±Õ °¨¿°ÀÇ ÆÄ±Þ¿¡ ÀÇÇÏ¿© ¹ß»ýÇϸç, ¸²ÇÁ°üÀÇ °æ·Î¿¡ µû¶ó ÇÇÇÏ¿¡ ºÓÀº µ¿Å뼺 ÁÙ¹«´Ì°¡ ³ªÅ¸³­´Ù.
  • acute lymphoblastic leukemia
    ±Þ¼º ¸²ÇÁ¼º ¹éÇ÷º´
    1. À¯¾Æ ¹× ÀþÀº ¼ºÀο¡ È£¹ßÇÏ´Â Áúȯ. À¯¾Æ ±Þ¼º ¹éÇ÷º´ÀÇ »ó´ç¼ö¸¦ Â÷ÁöÇÑ´Ù. À¯¾Æ¿¡¼­ÀÇ È£¹ß ¿¬·ÉÀº 4¼¼ ÀüÈÄ. ÃÖ±Ù È­Çпä¹ýÀ¸·Î º´¿¡ °É¸° À¯¾ÆÀÇ 90%°¡ ¿ÏÀü Ä¡À¯µÈ´Ù. ¿¹ÈÄ´Â ¿¬·É, ¸é¿ªÇ¥ÇöÇü ±×¸®°í ¼¼Æ÷ À¯ÀüÇÐÀûÀÎ º¯È­¿¡ ÀÇÇØ ¿µÇâÀ» ¹Þ´Â´Ù. 2. ȯÀÚÀÇ 90%°¡ ¹éÇ÷±¸ ¼¼Æ÷¿¡¼­ ÇÙÇü ÀÌ»óÀ» º¸ÀδÙ. ÀϺΠ¼¼Æ÷À¯Àü º¯È­°¡ ¼ºº°, ¿¬·É, ¸é¿ªÇ¥ÇöÇü °°Àº º¯ÀÌ¿ä¼Ò¿Í »ó°ü¾øÀÌ ¿¹ÈÄ¿¡ ´ëÇÑ Á¤º¸¸¦ ÁØ´Ù. 51-60 ¿°»öü »çÀÌÀÇ °í¹è¼ö¼ºÀÌ ¿¹Èİ¡ ÁÁÀº °ÍÀº ÀÌ¹Ì Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • acute mania
    ±Þ¼º Á¶Áõ, ±Þ¼º Á¶º´
  • acute mastoiditis
    ±Þ¼º À¯¾çµ¹±â¿°
    À¯¾çµ¹±âÀÇ ±Þ¼º ¿°Áõ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
hepatitis b vaccines Vaccines or candidate vaccines containing inactivated hepatitis b or some of its component antigens and designed to prevent hepatitis b. Some vaccines may be recombinantly produced.
(12 Dec 1998)
hepatitis b virus The type species of the genus orthohepadnavirus which causes human hepatitis b and is also apparently a causal agent in human hepatocellular carcinoma. The dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.
(12 Dec 1998)
hepatitis b virus, duck A DNA virus that closely resembles human hepatitis b virus. It has been recovered from naturally infected ducks.
(12 Dec 1998)
hepatitis b virus, woodchuck An orthohepadnavirus causing chronic liver disease and hepatocellular carcinoma in woodchucks. It closely resembles the human hepatitis b virus.
(12 Dec 1998)
hepatitis C <virology> A form of viral hepatitis, previously referred to as nonA nonB hepatitis, is the most common form of blood transfusion acquired hepatitis. Transmission through sexual contact is considered rare. Risk factors include recent blood transfusion, IV drug abuse or occupational exposure to blood products. There is no specific treatment. There is a test for hepatitis C antibody which indicates prior exposure. Unlike hepatitis b there is no marker yet identifiable for those who suffer from chronic hepatitis C.
(27 Sep 1997)
hepatitis c antibodies Antibodies to the hepatitis c antigens including antibodies to envelope, core, and non-structural proteins.
(12 Dec 1998)
hepatitis c antigens Antigens of the virions of hepatitis c-like viruses, their surface, core, or other associated antigens.
(12 Dec 1998)
hepatitis c, chronic An inflammatory disease of the liver caused by hepatitis c virus lasting six months or more.
(12 Dec 1998)
hepatitis, chronic A collective term for a clinical and pathological syndrome which has several causes and is characterised by varying degrees of hepatocellular necrosis and inflammation. Specific forms of chronic hepatitis include autoimmune hepatitis (hepatitis, autoimmune), chronic hepatitis b (hepatitis b, chronic), chronic hepatitis c (hepatitis c, chronic), chronic hepatitis d (hepatitis d, chronic), indeterminate chronic viral hepatitis, cryptogenic chronic hepatitis and drug-related chronic hepatitis (hepatitis, chronic, drug-induced).
(12 Dec 1998)
hepatitis, chronic, drug-induced An inflammatory disease of the liver, lasting six months or more, and caused by an adverse drug effect. The adverse effect may result from a direct toxic effect of a drug or metabolite, or an idiosyncratic response to a drug or metabolite. The clinical and histological changes can mimic viral or autoimmune hepatitis.
(12 Dec 1998)
hepatitis c-like viruses A genus of flaviviridae causing parenterally-transmitted non-a, non-b hepatitis (hepatitis c) which is associated with transfusions and drug abuse. Hepatitis c virus is the type species.
(12 Dec 1998)
hepatitis contagiosa canis A disease of dogs, caused by canine adenovirus 1, and characterised by fever, depression, loss of appetite, vomiting, bloody diarrhoea, petechial haemorrhages in the gums, pale mucous membranes, and jaundice.
Synonym: hepatitis contagiosa canis, Rubarth's disease.
(05 Mar 2000)
hepatitis C virus A non-A, non-B RNA virus causing post-transfusion hepatitis; it appears to be a member of the family Flaviviridae.
(05 Mar 2000)
hepatitis D <virology> A rare form of viral transfusion hepatitis. A defective viral agent that occurs only in association with hepatitis B infection. The delta agent may also increase the severity of hepatitis B infection. Complications include chronic persistent hepatitis and fulminant hepatitis. A test known as anti-delta agent antibody is positive and used to confirm the diagnosis. Treatment is the same as for hepatitis B.
(27 Sep 1997)
hepatitis d, chronic Inflammatory disease of the liver caused by hepatitis d virus in conjunction with hepatitis b virus and lasting six months or more.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á